This review examines the use of dimercaptosuccinic acid (DMSA or succimer) in treating inorganic lead poisoning. DMSA is an orally administered chelating agent that effectively increases urinary excretion of lead and lowers blood lead levels. It is well absorbed, binds to plasma proteins, and is excreted primarily via the kidneys.
This review examines the use of metal chelators, including DMSA, DMPS, and CaEDTA, in treating lead, mercury, and arsenic poisoning, with a focus on their efficacy, safety, and potential combination therapies. The study highlights that DMSA is a safer alternative to CaEDTA for moderate lead poisoning and suggests that DMSA
This review examines the effectiveness and safety of four chelating agents—DMSA, DMPS, CaNa₂EDTA, and BAL—for treating heavy metal poisoning, particularly lead, mercury, and arsenic intoxication. The study highlights that DMSA and DMPS are safer and more effective alternatives to traditional chelators like CaNa₂EDTA and BAL, with DMSA primarily used for
This review compares the effectiveness, pharmacokinetics, and adverse effects of sodium calcium edetate (CaNa2EDTA) and succimer (DMSA) for treating inorganic lead poisoning. Both agents are effective in enhancing lead excretion and reducing blood lead levels, with DMSA being more effective in reducing kidney lead concentrations and CaNa2EDTA more effective for
Chelation therapy, developed in the 1930s with the synthesis of EDTA, was initially used during World War II to treat heavy metal poisoning. In the 1950s, it was observed that patients receiving chelation therapy for lead poisoning experienced improvements in conditions like angina pectoris, suggesting potential cardiovascular benefits. Over time,
